Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.

Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

Results from Novo Nordisk's STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight ...

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable. In the Phase ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Novo Nordisk (NVO) reported headline results from STEP UP, a phase 3b trial in the global STEP programme. The trial achieved primary ...

Shares of Novo Nordisk (NYSE:NVO) fell 2% following the announcement of results from its STEP UP obesity trial, which showed ...

Novo Nordisk's STEP UP trial shows semaglutide 7.2 mg delivers superior weight loss and safety compared to lower doses and ...

Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...

Novo Nordisk (NVO) stock slipped after ate-stage trial data for a higher-dose version of its popular obesity therapy, ...